KR102859911B1 - IgE-매개 알레르기성 질환들의 치료 - Google Patents

IgE-매개 알레르기성 질환들의 치료

Info

Publication number
KR102859911B1
KR102859911B1 KR1020207014545A KR20207014545A KR102859911B1 KR 102859911 B1 KR102859911 B1 KR 102859911B1 KR 1020207014545 A KR1020207014545 A KR 1020207014545A KR 20207014545 A KR20207014545 A KR 20207014545A KR 102859911 B1 KR102859911 B1 KR 102859911B1
Authority
KR
South Korea
Prior art keywords
antibody
pharmaceutical composition
dose
composition according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014545A
Other languages
English (en)
Korean (ko)
Other versions
KR20200110302A (ko
Inventor
쿵-밍 루
니엔-이 첸
티엔-티엔 쳉
Original Assignee
원니스 바이오테크 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원니스 바이오테크 컴퍼니 리미티드 filed Critical 원니스 바이오테크 컴퍼니 리미티드
Publication of KR20200110302A publication Critical patent/KR20200110302A/ko
Application granted granted Critical
Publication of KR102859911B1 publication Critical patent/KR102859911B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207014545A 2017-10-31 2018-10-30 IgE-매개 알레르기성 질환들의 치료 Active KR102859911B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579416P 2017-10-31 2017-10-31
US62/579,416 2017-10-31
PCT/CN2018/112714 WO2019085902A1 (en) 2017-10-31 2018-10-30 Treating ige-mediated allergic diseases

Publications (2)

Publication Number Publication Date
KR20200110302A KR20200110302A (ko) 2020-09-23
KR102859911B1 true KR102859911B1 (ko) 2025-09-16

Family

ID=66332803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014545A Active KR102859911B1 (ko) 2017-10-31 2018-10-30 IgE-매개 알레르기성 질환들의 치료

Country Status (13)

Country Link
US (2) US11439682B2 (enExample)
EP (1) EP3703753A4 (enExample)
JP (1) JP7286665B2 (enExample)
KR (1) KR102859911B1 (enExample)
CN (1) CN111741768B (enExample)
AU (1) AU2018360999A1 (enExample)
BR (1) BR112020008488A2 (enExample)
CA (1) CA3079992A1 (enExample)
IL (1) IL277911B2 (enExample)
MX (1) MX421215B (enExample)
TW (1) TWI821209B (enExample)
WO (1) WO2019085902A1 (enExample)
ZA (1) ZA202002247B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304509A (zh) * 2021-04-02 2023-02-01 合一生技股份有限公司 高濃度抗體製劑
US20230122862A1 (en) * 2021-10-12 2023-04-20 United BioPharma, Inc. Treatment of ige-mediated diseases
CN114028731B (zh) * 2021-12-10 2024-01-26 固安翌光科技有限公司 腰部塑形光疗装置

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5274075A (en) 1987-12-31 1993-12-28 Tanox Biosystems, Inc. Newly identified human epsilon immunoglobulin peptides and related products
US5484907A (en) 1989-06-21 1996-01-16 Tanox Biosystems, Inc. Nucleotides coding for the extracellular membrane-bound segment of IgA
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
US5362643A (en) 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5254671A (en) 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5260416A (en) 1987-12-31 1993-11-09 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgE
US5079344A (en) 1989-06-21 1992-01-07 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted IgA
EP0407392B2 (en) 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5690934A (en) 1987-12-31 1997-11-25 Tanox Biosystems, Inc. Peptides relating to the extracellular membrane-bound segment of human alpha chain
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5514776A (en) 1987-12-31 1996-05-07 Tanox Biosystems, Inc. Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5310875A (en) 1989-06-21 1994-05-10 Tanox Biosystems, Inc. Peptides corresponding to membrane-bound IgA
ATE148348T1 (de) 1989-09-15 1997-02-15 Tanox Biosystems Inc Behandlung von einer autoimmun-krankheit
DK0512064T3 (da) 1990-01-23 1997-12-15 Tanox Biosystems Inc Ekstracellulære segmenter af human IgE immuno-globulinforankringspeptider og for disse specifikke antistoffer
US5281699A (en) 1990-06-01 1994-01-25 Tanox Biosystems, Inc. Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
WO1992007574A1 (en) 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CN1167491A (zh) 1994-10-25 1997-12-10 美国联合生物医学公司 用于治疗变态反应的合成IgE膜锚肽免疫原
WO1998053843A1 (en) 1997-05-30 1998-12-03 Tanox Biosystems, Inc. INHIBITION OF ANTIGEN-SPECIFIC IgE PRODUCTION BY ANTIGEN COUPLED TO MEMBRANE IgE PETIDE
EP2361635A3 (en) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
AUPS158502A0 (en) 2002-04-08 2002-05-16 Dermcare-Vet Pty Ltd Allergic dermatitis composition and method of treatment
EP1941275B1 (en) 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US20090220416A1 (en) 2006-05-03 2009-09-03 Sydney Welt Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
WO2008116149A2 (en) 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti- ige antibodies binding the membrane-bound ige
HUE036920T2 (hu) 2009-02-25 2018-08-28 Academia Sinica Anti-C[epszilon]mX-ellenanyagok, amelyek képesek B-limfocitákon humán mlgE-hez kötõdni
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
WO2011108008A2 (en) 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
EP2838919A4 (en) * 2012-04-20 2016-03-23 Academia Sinica ANTIBLE ANTIBODIES BINDING TO THE TRANSITION BETWEEN CH4 AND C EPSILON MX DOMAINS
RU2698907C2 (ru) * 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
JP6068582B2 (ja) * 2015-08-07 2017-01-25 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体

Also Published As

Publication number Publication date
CN111741768A (zh) 2020-10-02
US20200297815A1 (en) 2020-09-24
JP7286665B2 (ja) 2023-06-05
CA3079992A1 (en) 2019-05-09
IL277911A (en) 2020-11-30
MX421215B (es) 2025-02-10
EP3703753A1 (en) 2020-09-09
KR20200110302A (ko) 2020-09-23
WO2019085902A1 (en) 2019-05-09
EP3703753A4 (en) 2021-08-18
TW201929899A (zh) 2019-08-01
US12083161B2 (en) 2024-09-10
MX2020004469A (es) 2020-09-07
IL277911B2 (en) 2025-07-01
US11439682B2 (en) 2022-09-13
AU2018360999A1 (en) 2020-05-14
US20230100100A1 (en) 2023-03-30
RU2020117749A3 (enExample) 2022-01-31
ZA202002247B (en) 2022-01-26
RU2020117749A (ru) 2021-12-02
IL277911B1 (en) 2025-03-01
TWI821209B (zh) 2023-11-11
CN111741768B (zh) 2024-12-27
BR112020008488A2 (pt) 2020-10-20
JP2021501213A (ja) 2021-01-14

Similar Documents

Publication Publication Date Title
US12083161B2 (en) Treating IgE-mediated allergic diseases
UA124269C2 (uk) Застосування антагоністу il-13 для лікування атопічного дерматиту
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
JP2017512790A (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
JP2016513682A (ja) 抗血漿カリクレイン抗体
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
WO2021195530A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20190141148A (ko) 소아 장애를 치료하는 방법
CN116782934A (zh) 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
US20220348687A1 (en) Dosing for anti-tryptase antibodies
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
US20250059289A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
WO2022089595A1 (en) Biomarkers for ige-mediated diseases
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
WO2024261177A1 (en) Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
CN117715938A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
TW202021615A (zh) Ｐｃｓｋ９抑制劑用於治療高血脂症的用途
EA045947B1 (ru) Моноклональное антитело-ингибитор фактора xiia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)